tesofensine protocol FAQ

Discard the vial and document it as compromised. Room-temperature exposure for 8+ hours initiates hydrolysis of peptide bonds and oxidation of aromatic structures. Degradation products remain in solution but no longer bind monoamine transporters with the same affinity as intact tesofensine. The solution may still appear clear and colorless, creating false confidence. Potency loss from overnight ambient storage is typically 20–40% based on similar peptide degradation studies, meaning dosing calculations become meaningless. If results from that vial are already recorded, flag them as potentially invalid and consider repeating those data points with fresh compound.

Contact the supplier immediately with shipping tracking details and request replacement. Reputable peptide suppliers like Real Peptides include temperature monitoring or pack lyophilised compounds with sufficient cold packs to maintain sub-zero temperatures for 48–72 hours. If the cold pack is warm or the insulation compromised upon arrival, the peptide has likely experienced freeze-thaw cycles or extended periods above −15°C during transit. Partial degradation during shipping is invisible but cumulative. Using compromised compound introduces baseline variability that contaminates all downstream results.

Stop using the vial immediately and inspect for particulates under bright light. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the solution unusable. Bacterial growth typically presents as diffuse haziness with or without visible colonies; peptide aggregation appears as fine suspended particles or flocculent material. Neither condition is reversible. If cloudiness appeared within the first week post-reconstitution, it suggests contamination during the reconstitution process itself. Review aseptic technique and ensure bacteriostatic water was used, not sterile water. If cloudiness developed after 2–3 weeks, it may indicate repeated contamination events from improper stopper swabbing during multi-dose draws.

Administer the peptide at least 90 minutes before or after carbohydrate-containing meals to prevent insulin-mediated suppression of lipolysis. Elevated insulin directly inhibits hormone-sensitive lipase (HSL), the enzyme AOD-9604 activates to break down stored triglycerides. Research shows FFA elevation drops by 40–50% when the peptide is given within 60 minutes of glucose intake. If meal timing conflicts with the twice-daily protocol, shift administration to true fasted windows. Upon waking and mid-afternoon at least three hours post-lunch.

Reassess total energy intake. The most common cause of plateau is unconscious caloric drift where intake gradually increases to match the new energy expenditure baseline. Tesofensine maintains appetite suppression, but it doesn't eliminate the possibility of consuming maintenance-level calories through larger portion sizes or higher meal frequency. Objective food logging typically reveals 200–400 calorie/day increases that offset continued fat oxidation. The protocol itself remains effective; the deficit simply disappeared.

Reduce the dose to 0.25 mg daily and monitor cardiovascular parameters for one week before discontinuing. Norepinephrine reuptake inhibition increases sympathetic tone, which can elevate resting heart rate by 5–10 bpm and systolic blood pressure by 3–7 mmHg in sensitive individuals. These effects are dose-dependent and typically resolve with dose reduction. If cardiovascular changes persist at 0.25 mg or baseline heart rate exceeds 90 bpm at rest, the compound is contraindicated and should not be used in that research protocol.